| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.272.31.19236 |
| P953 | full work available online at | http://www.jbc.org/article/S0021925818389488/pdf |
| https://api.elsevier.com/content/article/PII:S0021925818389488?httpAccept=text/plain | ||
| https://api.elsevier.com/content/article/PII:S0021925818389488?httpAccept=text/xml | ||
| https://syndication.highwire.org/content/doi/10.1074/jbc.272.31.19236 | ||
| P3181 | OpenCitations bibliographic resource ID | 715994 |
| P698 | PubMed publication ID | 9235916 |
| P2093 | author name string | D. Chantry | |
| P. W. Gray | |||
| J. A. Cooper | |||
| C. Wood | |||
| D. A. Holtzman | |||
| M. F. Hoekstra | |||
| A. Kashishian | |||
| A. Vojtek | |||
| P2860 | cites work | Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling | Q24313633 |
| A single ataxia telangiectasia gene with a product similar to PI-3 kinase | Q24323579 | ||
| DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product | Q24337388 | ||
| Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85 | Q24629213 | ||
| An analysis of vertebrate mRNA sequences: intimations of translational control | Q24642530 | ||
| Mammalian Ras interacts directly with the serine/threonine kinase Raf | Q27860833 | ||
| Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase | Q28115936 | ||
| Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit | Q28211409 | ||
| PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells | Q28236975 | ||
| Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate | Q28280837 | ||
| Identification and characterization of a cDNA encoding mouse CAP: a homolog of the yeast adenylyl cyclase associated protein | Q28592297 | ||
| The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101 | Q28678835 | ||
| Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun | Q29620103 | ||
| Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase | Q29620178 | ||
| Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases | Q30195688 | ||
| cDNA cloning of a Novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF β-receptor | Q30195693 | ||
| Expression of cellular protooncogenes in the mouse male germ line: a distinctive 2.4-kilobase pim-1 transcript is expressed in haploid postmeiotic cells | Q33563405 | ||
| Anti-inflammatory properties of a platelet-activating factor acetylhydrolase | Q34307399 | ||
| Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes | Q35334408 | ||
| Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28 | Q38336999 | ||
| When is a lipid kinase not a lipid kinase? When it is a protein kinase | Q40410589 | ||
| Upstream-downstream: CD28 cosignaling pathways and T cell function | Q41010604 | ||
| The Atr and Atm protein kinases associate with different sites along meiotically pairing chromosomes. | Q41164271 | ||
| Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase | Q42828607 | ||
| A target for Pl(3) kinase | Q57903782 | ||
| Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins | Q70787161 | ||
| Intracellular signalling. PI 3-kinase puts GTP on the Rac | Q71725584 | ||
| Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor | Q72121269 | ||
| Phosphatidyl-inositol 3-kinase: a key enzyme in diverse signalling processes | Q75294024 | ||
| P433 | issue | 31 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | Q7117825 |
| 1-phosphatidylinositol-3-kinase activity | Q14872781 | ||
| P304 | page(s) | 19236-41 | |
| P577 | publication date | 1997-08-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes | |
| p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes | |||
| P478 | volume | 272 |
| Q54977058 | "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology. |
| Q28574136 | A Novel Class II Phosphoinositide 3-Kinase Predominantly Expressed in the Liver and Its Enhanced Expression during Liver Regeneration |
| Q28202234 | A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation |
| Q33781691 | A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction |
| Q35159659 | A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling |
| Q83350735 | A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16 |
| Q41791633 | Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. |
| Q57092190 | Associations of high-altitude polycythemia with polymorphisms in PIK3CD and COL4A3 in Tibetan populations |
| Q50291477 | BCAP Signalosome phosphorylates PI(4,5)P2 forming PI(3,4,5)P3 |
| Q39642145 | CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability |
| Q37960157 | CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies |
| Q28115490 | CCR11 is a functional receptor for the monocyte chemoattractant protein family of chemokines |
| Q50291478 | CD19 Signalosome phosphorylates PI(4,5)P2 forming PI(3,4,5)P3 |
| Q35808718 | Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers |
| Q57491434 | Class-Switch Recombination (CSR)/Hyper-IgM (HIGM) Syndromes and Phosphoinositide 3-Kinase (PI3K) Defects |
| Q34508976 | Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment |
| Q37626141 | Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study |
| Q54442252 | Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors |
| Q34037865 | Constitutive AKT activation in follicular lymphoma |
| Q33298503 | Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase |
| Q41615168 | Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells |
| Q48229900 | Differential mRNA expression and subcellular locations of PI3-kinase isoforms in sympathetic and sensory neurons |
| Q40724764 | Distinct roles of phosphoinositide-3 kinase and phospholipase Cgamma2 in B-cell receptor-mediated signal transduction |
| Q34380652 | Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency |
| Q38222824 | Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma |
| Q38637153 | ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor |
| Q28288981 | Essential role for the p110delta phosphoinositide 3-kinase in the allergic response |
| Q29615120 | Exploiting the PI3K/AKT pathway for cancer drug discovery |
| Q53742280 | High level of p37δ-mRNA relative to p110δ-mRNA in neuroblastoma tumors correlates with poor patient survival. |
| Q28818948 | High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib |
| Q38850667 | Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Q37114445 | Idelalisib for the treatment of non-Hodgkin lymphoma. |
| Q38364936 | Idelalisib- a PI3Kδ targeting agent for B-cell malignancies |
| Q26865645 | Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma |
| Q54176830 | Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice. |
| Q42795770 | Identification and Characterization of Mutations in Ha-Ras That Selectively Decrease Binding to cRaf-1 |
| Q41060477 | Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase |
| Q35221546 | Identification of Mutations that Delay Somatic or Reproductive Aging of Caenorhabditis elegans |
| Q40216172 | Immunodeficiency-Associated Lymphoid Hyperplasia As a Cause of Intussusception in a Case of Activated PI3K-δ Syndrome |
| Q47153501 | Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model. |
| Q38852858 | Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms |
| Q30440798 | Insulin and glucose play a role in foam cell formation and function |
| Q40933654 | Intracellular movement of green fluorescent protein-tagged phosphatidylinositol 3-kinase in response to growth factor receptor signaling |
| Q28215324 | Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation |
| Q41789259 | Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter |
| Q41881074 | Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo |
| Q73759952 | Isolation of effector-selective Ras mutants by yeast two-hybrid screening |
| Q38193070 | Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies |
| Q36598687 | Leptin signaling and circuits in puberty and fertility |
| Q38366294 | Management of adverse events associated with idelalisib treatment: expert panel opinion |
| Q27006068 | Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia |
| Q38666875 | Molecules in medicine mini-review: isoforms of PI3K in biology and disease |
| Q52592631 | Monitoring and Management of Toxicities of Novel B Cell Signaling Agents |
| Q37968309 | Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking |
| Q26801832 | Myeloid Cells as Targets for Therapy in Solid Tumors |
| Q26828496 | New strategies in chronic lymphocytic leukemia: shifting treatment paradigms |
| Q54557736 | Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628 |
| Q27011763 | Novel agents in mantle cell lymphoma |
| Q38081658 | Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase. |
| Q34335162 | Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase |
| Q26781367 | PI3K and AKT: Unfaithful Partners in Cancer |
| Q26770489 | PI3K inhibitors as new cancer therapeutics: implications for clinical trial design |
| Q93240079 | PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression |
| Q54527804 | PI3K signalling: the path to discovery and understanding |
| Q37032524 | PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects |
| Q34195495 | PI3K: from the bench to the clinic and back |
| Q38542387 | PI3King the right partner: unique interactions and signaling by p110β. |
| Q47169310 | Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma |
| Q55254953 | Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. |
| Q37418266 | Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis |
| Q36601779 | Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections |
| Q47754054 | Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia |
| Q54567439 | Phosphatidylinositol 3-kinase inhibitor suppresses inducible nitric oxide synthase expression in bronchiole epithelial cells in asthmatic rats |
| Q30492383 | Phosphatidylinositol 3-kinase/protein kinase Cdelta activation induces close homolog of adhesion molecule L1 (CHL1) expression in cultured astrocytes |
| Q36737287 | Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia |
| Q37010509 | Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse. |
| Q48019225 | Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches |
| Q38229531 | Phosphoinositide 3-kinase inhibitors in lymphoma |
| Q33633092 | Phosphoinositide 3-kinase p110δ mediates estrogen- and FSH-stimulated ovarian follicle growth |
| Q36872061 | Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. |
| Q40808389 | Phosphoinositide 3-kinase-dependent regulation of interleukin-3-induced proliferation: involvement of mitogen-activated protein kinases, SHP2 and Gab2. |
| Q24291200 | Prenylated Rab acceptor protein is a receptor for prenylated small GTPases |
| Q33428537 | Regulation of p110delta PI 3-kinase gene expression |
| Q35635133 | Rhinovirus activates interleukin-8 expression via a Src/p110beta phosphatidylinositol 3-kinase/Akt pathway in human airway epithelial cells. |
| Q35203309 | Role of phosphoinositide 3-kinase signaling in mast cells: new insights from knockout mouse studies. |
| Q42790948 | Role of the p110delta PI 3-kinase in integrin and ITAM receptor signalling in platelets |
| Q44555476 | Selective role of PI3K delta in neutrophil inflammatory responses |
| Q34350383 | Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors |
| Q24309044 | Should individual PI3 kinase isoforms be targeted in cancer? |
| Q43737697 | Signaling mechanism for equine neutrophil activation by immune complexes |
| Q37619784 | Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies |
| Q39766760 | Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation |
| Q35096703 | T cell anergy and costimulation |
| Q33861767 | TC21 and Ras share indistinguishable transforming and differentiating activities |
| Q61813482 | Targeting PI3K Signaling in Acute Lymphoblastic Leukemia |
| Q38113583 | Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia |
| Q36163034 | The B-cell receptor signaling pathway as a therapeutic target in CLL. |
| Q36214120 | The Expression of CD9 and PIK3CD is Associated with Prognosis of Follicular Lymphoma |
| Q28610410 | The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3 |
| Q41670884 | The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. |
| Q35665386 | The Unique Non-Catalytic C-Terminus of P37delta-PI3K Adds Proliferative Properties In Vitro and In Vivo |
| Q24647037 | The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature |
| Q35133782 | The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation |
| Q27659013 | The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors |
| Q40708569 | The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. |
| Q40575812 | The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. |
| Q37454384 | The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. |
| Q36150234 | The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. |
| Q36523759 | The role of phosphoinositide 3-kinase subunits in chronic thyroiditis. |
| Q42372842 | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? |
| Q37728043 | ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system |
| Q36647928 | p110δ PI3 kinase pathway: emerging roles in cancer |
Search more.